Text Size

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00096603
First received: November 12, 2004
Last updated: November 14, 2005
Last verified: November 2005
History of Changes
  Purpose

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.


Condition Intervention Phase
Psoriasis
 Drug: Raptiva (efalizumab)
 Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter Study to Evaluate the Safety of 1.0 Mg/Kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Resource links provided by NLM:

MedlinePlus related topics: Psoriasis
U.S. FDA Resources

Further study details as provided by Genentech:

Estimated Enrollment: 450
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Previous participation in Study ACD2600g
  • For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion Criteria:

  • Any medical condition that, in the judgment of the investigator, would jeopardize the subject’s safety following exposure to Efalizumab
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Additional Information:
Study Results  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00096603     History of Changes
Other Study ID Numbers: ACD2601g
Study First Received: November 12, 2004
Last Updated: November 14, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech:
Moderate to severe plaque psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013